Notably, individuals with the 19‐Del mutation who received EGFR‐TKIs combined with thoracic or bone metastasis radiotherapy exhibited greater benefits compared with those with the 21‐L858R mutation (mOS: 51.0 vs. 30.15 months, p = 0.0013; 34.7 vs. 25.15 months, p = 0.0056, respectively). The gene discussed is EGFR; the disease is bone metastasis.